private:newhavenpharmaceuticals
|
786122
|
May 30th, 2019 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
943
|
7.00
|
Open
|
Pharmaceuticals
|
May 30th, 2019 01:56PM
|
May 30th, 2019 01:56PM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
Open
|
Pharmaceuticals, Gastrointestinal, Cardiovascular
|
Open
|
116 Washington Avenue
|
North Haven
|
CT
|
US
|
06473
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 17th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 16th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 15th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 14th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 13th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 12th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 11th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 10th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
private:newhavenpharmaceuticals
|
786122
|
Feb 9th, 2018 12:00AM
|
New Haven Pharmaceuticals, Inc.
|
919
|
11.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.
By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.
Most importantly, the Company's innovative approach—emphasizing collaboration and problem-solving—means that New Haven Pharmaceuticals can develop drugs quickly and safely so that physicians can prescribe new therapies to patients who need relief as soon as possible.
|
|
|
|
|
|
|
|
|
|
New Haven Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|